{"id":761047,"date":"2026-06-25T21:34:29","date_gmt":"2026-06-25T21:34:29","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/761047\/"},"modified":"2026-06-25T21:34:29","modified_gmt":"2026-06-25T21:34:29","slug":"hcq-blood-level-monitoring-linked-to-better-disease-control-in-sle","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/761047\/","title":{"rendered":"HCQ Blood Level Monitoring Linked to Better Disease Control in SLE"},"content":{"rendered":"<p>Maintaining therapeutic hydroxychloroquine (HCQ) blood levels is associated with lower odds of active systemic lupus erythematosus (SLE) and flares over time, while subtherapeutic levels are linked to worse disease control, according to study results published in Arthritis Care &amp; Research.<\/p>\n<p><a href=\"https:\/\/www.empr.com\/drug\/plaquenil\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Hydroxychloroquine<\/a> is a foundational therapy in SLE and prolongs disease-free and damage-free survival. Current guidance supports weight-based dosing to reduce ocular toxicity, but dosing does not account for interpatient variability in metabolism, absorption, <a href=\"https:\/\/www.rheumatologyadvisor.com\/news\/medication-nonadherence-decreases-with-age-in-sle\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">adherence<\/a>, or renal clearance. Longitudinal data evaluating whether HCQ blood level monitoring improves outcomes and informs dose adjustment have been limited.<\/p>\n<p>Investigators analyzed data from a prospective longitudinal SLE cohort at the University of Wisconsin Collaborative SLE clinics. Eligible adults had validated <a href=\"https:\/\/www.rheumatologyadvisor.com\/news\/anti-ssa-ro-antibodies-not-linked-to-apos-in-sle\/\" rel=\"nofollow noopener\" target=\"_blank\">SLE<\/a>, had received HCQ for at least 3 months before enrollment, and were followed with repeated clinic visits that included HCQ blood levels obtained at least 6 hours after the last dose and disease activity assessments.<\/p>\n<p>HCQ blood level monitoring could improve SLE control, particularly in patients with eGFR \u226475, and enable optimal HCQ use.<\/p>\n<p>Generalized linear mixed models with random intercepts and slopes were used to evaluate associations between clinical variables, HCQ blood levels, and active SLE over time, with additional within-subject and between-subject decomposition analyses.<\/p>\n<p>The analysis included 247 patients who contributed 962 visits, with an average of 4 visits per patient and 2 years of follow-up. At baseline, the mean age was 47 years, 91% of patients were women, 66% were White, and 46% had HCQ levels below 750 ng\/mL. The mean HCQ blood level across visits was 815\u00b1482 ng\/mL and 79.1% of visits involved HCQ doses of 5 mg\/kg\/day or less.<\/p>\n<p>Very low HCQ levels (&lt;200 ng\/mL) and subtherapeutic levels (200 to &lt;750 ng\/mL) were associated with higher odds of active SLE vs therapeutic levels (750-1149 ng\/mL), with odds ratios (ORs) of 6.65 (95% CI, 2.07-21.36; P =.001) and 2.57 (95% CI, 1.17-5.70; P =.02), respectively.<\/p>\n<p>Each 100 ng\/mL increase in HCQ blood levels over time was associated with 12% lower odds of active SLE (OR, 0.88; 95% CI, 0.81-0.95; P =.002), while within-patient increases of 100 ng\/mL predicted 33% lower odds of active SLE and 22% lower odds of flare (OR, 0.78; 95% CI, 0.62-0.98; P =.03 for flare).<\/p>\n<p>Patients who maintained therapeutic HCQ levels at all visits had 83% lower odds of active SLE compared with those who remained persistently subtherapeutic (OR, 0.17; 95% CI, 0.04-0.75; P =.02).<\/p>\n<p>Study limitations include the single academic-center design, the inability to compare data from patients with acute kidney injury vs chronic kidney disease, and possible residual confounding related to immunosuppressant changes.<\/p>\n<p>\u201cHCQ blood level monitoring could improve SLE control, particularly in patients with eGFR \u226475, and enable optimal HCQ use,\u201d the study authors concluded.<\/p>\n<p>Disclosure: Some study authors declared affiliations with biotech, pharmaceutical, and\/or device companies. Please see the original reference for a full list of disclosures.<\/p>\n<p>This article originally appeared on <a href=\"https:\/\/www.rheumatologyadvisor.com\/news\/hcq-blood-level-monitoring-linked-to-better-lupus-control\/\" target=\"_blank\" rel=\"nofollow noopener\">Rheumatology Advisor<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Maintaining therapeutic hydroxychloroquine (HCQ) blood levels is associated with lower odds of active systemic lupus erythematosus (SLE) and&hellip;\n","protected":false},"author":2,"featured_media":261476,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[49,48,84],"class_list":["post-761047","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-ca","tag-canada","tag-health"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/761047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=761047"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/761047\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/261476"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=761047"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=761047"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=761047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}